The US Food and Drug Administration (FDA) has cleared MindMotion GO (MindMaze), a mobile neurorehabilitation therapy system designed to motivate and engage patients in daily rehabilitation, the company reports
MindMotion GO is designed to be used by patients with light- and medium-severity neurologic impairments and also provides continued therapy later in the recovery phase, primarily on an outpatient basis, the company says.
MindMotion GO is an outpatient addition to the company’s MindMotion PRO, which received FDA approval in May 2017. MindMotion PRO is designed for patients with severe impairments and for early hospital care, allowing for therapeutic activities as early as 4 days after a neurologic incident.
“Now that both MindMotion products have FDA clearance, MindMaze delivers a full spectrum of neuro-care solutions for both inpatient and outpatient recovery for patients in the United States,” Tej Tadi, CEO and founder of MindMaze, said in a news release.
The MindMotion GO neurorehabilitation therapy system includes a variety of gamified activities covering motor and task functions in a three-dimensional virtual environment.
The program offers real-time audio and visual feedback to help physicians assess a patient’s progress and tailor therapy based on their performance. Patients are also able to monitor their progress. The set-up and calibration can be done in less than 5 minutes, the company says.
MindMotion GO is designed to keep patients engaged and “increase therapy dose and recovery potential,” the company notes on its website.
MindMotion GO is currently available in Europe and has been trialed by more than 300 patients across therapy centers in the United Kingdom, Italy, Germany, and Switzerland.